Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
A 3-month evaluation of electrocardiographic effects of loratadine in healthy individuals
Autore:
Affrime, MB; Brannan, MD; Lorber, RR; Danzig, MR; Cuss, F;
Indirizzi:
Schering Plough Corp, Res Inst, Kenilworth, NJ 07033 USA Schering Plough Corp Kenilworth NJ USA 07033 st, Kenilworth, NJ 07033 USA
Titolo Testata:
ADVANCES IN THERAPY
fascicolo: 4, volume: 16, anno: 1999,
pagine: 149 - 157
SICI:
0741-238X(199907/08)16:4<149:A3EOEE>2.0.ZU;2-P
Fonte:
ISI
Lingua:
ENG
Soggetto:
TORSADES-DE-POINTES; NONSEDATING ANTIHISTAMINES; ASTEMIZOLE OVERDOSE; 2ND-GENERATION ANTIHISTAMINES; QT INTERVAL; TERFENADINE; CARDIOTOXICITY; ERYTHROMYCIN; CHANNELS;
Keywords:
loratadine; electrocardiographic; repolarization; arrhythmia; QT(c); antihistamine;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Citazioni:
24
Recensione:
Indirizzi per estratti:
Indirizzo: Affrime, MB Schering Plough Corp, Res Inst, 2015 Galloping Hill Rd,K-15-4,4455, Kenilworth, NJ 07033 USA Schering Plough Corp 2015 Galloping Hill Rd,K-15-4,4455 Kenilworth NJ USA 07033
Citazione:
M.B. Affrime et al., "A 3-month evaluation of electrocardiographic effects of loratadine in healthy individuals", ADV THER, 16(4), 1999, pp. 149-157

Abstract

This randomized, placebo-controlled, double-blind, outpatient study evaluated the effects of prolonged exposure to foul times the recommended daily dose of loratadine on electrocardiographic (ECG) parameters, including the QT(c) interval. Seventy adult men received either loratadine 40 mg once daily or placebo for 13 weeks. The primary safety variable was ECG parameters recorded at weeks 3, 5, 7, and 9, and 1 month after the final dose. No statistically significant mean change from baseline in any ECC parameter or individual trends suggesting QT(c) prolongation were observed. No patient had aQT(c) interval greater than 440 msec at any time point. Loratadine was well tolerated, and there were no reports of dizziness or syncope. Long-term administration of loratadine 40 mg once daily was well tolerated and produced no evidence of QT(c) interval prolongation or any other cardiac arrhythmias.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 24/06/18 alle ore 17:03:06